Bionano Genomics, Inc.

BNGO Healthcare Medical Instruments & Supplies

Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.25 0.12 −8.76%
Market cap
$16.1M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
5/9
Altman Z
−14.26
Beneish M
−3.39
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.43 0.45 0.29 0.32
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(2.79) (2.25) (2.00) (1.54)
P/B ratio
0.41 0.34 0.19 0.18
EV/Sales
0.67 0.20 (0.12) (0.17)
EV/EBITDA
0.00 0.00 0.14 0.18
EV/FCF
(0.99) (0.30) 0.21 0.27
Current Ratio
2.48 1.84 1.98 2.12
Net Debt/EBITDA
1.40 3.70 4.07 4.47
Debt/Equity
0.11 0.09 0.08 0.07
Earnings Yield
(267.26%) (373.50%) (311.11%) (689.32%)
Free Cash Flow Yield
(157.76%) (151.03%) (197.43%) (205.71%)
Free Cash Flow per Share
(0.40) (0.52) (0.77) (1.11)
Book value per Share
2.74 3.41 8.16 9.33
Free Cash Flow
(4.67) (5.72) (4.17) (5.92)
EV/EBIT
0.00 0.00 0.10 0.14
Other line items

Show all line items

Columns are period end dates